TrialAsia-Pacific journal of clinical oncology2019

A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.

Daijiro Harada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.